HK2 and glioblastoma: Regardless of the lack of information about HKII expression in TGCTs patients, several studies associated HKII overexpression with aggressive characteristics and worse outcomes in different types of neoplasms, such as breast (38–40), cervical (41), colorectal (42), glioblastoma (43), liver (44, 45), lung (39), pancreatic (46, 47) and prostate (48).